STARTING OXLUMO®(lumasiran)
NataliePerson with PH1*

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Dosing for OXLUMO

OXLUMO is given by a healthcare provider as an injection under the skin in the abdomen, thighs, or upper arms. Dosing is based on the patient’s weight.

Image
Dosing Table ‐ Dosing for OXLUMO happens in 2 phases

For patient on hemodialysis, OXLUMO will be administered after hemodialysis if administered on dialysis days.

For more information about how OXLUMO is given, talk to your doctor.
You can also refer to the Prescribing Information to learn more.

Image

How OXLUMO is given

OXLUMO is an injection administered by a healthcare provider. 

  • Injections are given under the skin
  • Injection sites can include the abdomen, thighs, or upper arms
  • Doses are usually given in a doctor’s office, though some patients may qualify for in-home nursing support, depending on their insurance coverage and doctor's recommendations

Want to know more about in-home nursing?

Learn About In-Home Nursing

Image

CONNECT WITH AN ALNYLAM EDUCATOR

Learn about primary hyperoxaluria type 1 (PH1) and treatment with OXLUMO® from one of our trained Alnylam Patient Education Liaisons (PELs).

PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.

Let’s Connect

Image

We’re here to help you access therapy

Find support services that can help you and your family during treatment with OXLUMO.

Let’s Go

Image

Sign up for updates

Learn more by signing up to receive important content.

Sign Me Up

NEXT:

DISCOVER SUPPORT SERVICES THAT ARE AVAILABLE FOR YOU AND YOUR FAMILY DURING TREATMENT

 PATIENT
SUPPORT

IMPORTANT SAFETY INFORMATION

The most common side effect of OXLUMO® (lumasiran) is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.

WHAT IS OXLUMO?

OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.  

For additional information about OXLUMO, please see full Prescribing Information.